Avricore Health Closes Upsized $1.254M Private Placement with Insider Participation
AVCRF has more than doubled off its 52-week low of $0.015.
Summary
Avricore Health closed a $1.254 million private placement at $0.05 per unit, upsized from the original $1.25 million, with insider participation of $200,000. The funds are earmarked for UK expansion amid a going-concern warning and severe revenue decline.
Key Events · Financing and Capital Events · AVCRF
-
Private Placement Closed
The company closed a non-brokered private placement on June 16, 2026, issuing 25,080,000 units at $0.05 per unit for gross proceeds of $1,254,000, upsized from the originally announced $1,250,000.
-
Insider Participation
Insiders, including certain directors and officers, purchased 4,000,000 units for $200,000, a related-party transaction exempt from formal valuation and minority approval requirements.
-
Finder's Fee
Canaccord Genuity Corp. received a cash commission of $54,600 and 1,092,000 non-transferable finder's warrants exercisable at $0.05 for two years.
-
Use of Proceeds
Proceeds will be used for general working capital, supporting the company's UK expansion strategy amid a going-concern warning and 89% revenue decline.
Analysis · AVCRF · Life Sciences
Avricore Health closed its previously announced private placement, raising $1.254 million—slightly above the $1.25 million target. The financing is critical for the company's UK expansion, especially given its going-concern warning and 89% revenue decline. Insiders put in $200,000, signaling commitment, but the deal is highly dilutive at $0.05 per unit with half-warrants exercisable at $0.10, potentially doubling the share count if exercised. The company's market cap is only about $5.7 million, so this raise is significant for extending its cash runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVCRF was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.02 to $0.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.